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IVF global histories, USA: between Rock and
a marketplace
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Choreography of Reproductive Technologies, and Good Science: The Ethical Choreography of Stem Cell Research. She
is a member of the Nuffield Council on the Bioethics Working Group on Genome Editing, and of the World Economic
Forum Global Future Council on Technology, Values, and Policy.Abstract The USA has played, and continues to play, a distinctive and significant part in the history of IVF and assisted reproductive
technology worldwide. American IVF emerged in the scientific context of contraceptive and fertility research, in the social context of
a wealthy nation without universal healthcare, and in the political context of the abortion debate and its impact on federal versus
state funding and regulation. IVF had its first clinical success in the USA in 1981. Since then, IVF in the USA has become known for
procedures involving third, fourth and fifth parties as gamete donors and surrogates. The USA has also been one of the pioneers in
domestic and transnational deployment of IVF for lesbian, gay, bisexual, transgender (LGBT) parenthood, and a pioneer of the social
egg-freezing revolution. US IVF has been marked by professional and patient advocacy for such things as the honest reporting of
success rates, recognition of the risks of postponed childbearing, and the need for insurance coverage. Certain landmark legal
custody disputes over IVF embryos and offspring, as well as media attention to gendered, racialized, and class-based access to and
pricing of assisted reproductive technology, have also driven the development of IVF in the USA.
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(http://creativecommons.org/licensesThe beginnings: biomedical research in
reproductive biologyIVF in the USA began experimentally in the context of hormone
and fertility research from the 1930s onwards. US scientists
such as Gregory Pincus, clinicians John Rock and Miriam
Menkin, and immigrants to the USA including Min Chue Chang,6.09.003
blished by Elsevier Ltd. This is an
/by-nc-nd/4.0/).were pioneers with mammalian IVF – largely in the context of
contraceptive research (Clarke, 1998). Pincus published the
first reports of successful mammalian IVF in the mid-1930s
(Pincus and Enzmann, 1936). Pincus was joined by MC Chang,
who was recruited from Cambridge University in 1945 to join
the newly formed Worcester Foundation of Experimental
Biology in Shrewsbury, Massachusetts (Chang, 1959). Pincus
and Chang, along with Rock and Menkin, would go on toopen access article under the CC BY-NC-ND license
129IVF Histories USAbecome experts in mammalian IVF, paving the way for its
eventual success in humans in the UK in 1978, and
co-developing the oral contraceptive pill (Eig, 2014).
Although it has subsequently been questioned andmay not,
in fact, have been achieved until 1969 (Edwards et al., 1969),
US researchers claimed, with the publication in 1944 of John
Rock’s and Miriam Menkin’s report in Science, to have
evidence of human fertilization in vitro. Relying on the ready
availability of surgically excised ovarian tissue, the article
records that Rock and Menkin used ‘surgical material available
at the Free Hospital for Women’ and that ‘nearly 800 human
follicular eggs’were ‘isolated and studied during the course of
this investigation; of these, 138 have been observed after
exposure to spermatozoa’ (Rock and Menkin, 1944). Abortion
and contraception were controversial in the 1940s, but the
idea of creating human embryos for research had not yet
become a front line of public ethical and scientific debate in
the USA, and gametes retrieved from surgical ‘waste’ tissue
were not considered to be morally controversial (Morgan,
2009). The TIME magazine article that reported on Rock and
Menkin’s research in the same year (TIME, 1944) famously
summed up the framing of the public debate at the time in
terms of man against nature, and an ‘affront to’ womanhood
and motherhood in the face of scientific reproduction:
Man will never be happy until he has proved that he is at least as
smart as nature. One thing hewould like to show theworld is that he
can reproduce himself scientifically. Artificial insemination was one
step. He took another step last week, with the first recorded
fertilization of a human ovum outside themother’s body. In Science
last week, Harvard gynecologist John Rock and his assistant, Miriam
F Menkin, reported this scientific affront to womanhood.
TIME'S 1944 framing, probably one of many even then,
would not maintain its domination. Once IVF became a clinical
possibility, the media focused more on fears of monsters and
religious objections than on a masculinist scientific mastery of
nature, and by the time the sector was well developed, into
the 21st century, nature would become as much an ally as a
victim of assisted reproductive technology with, for example,
IVF coming to be seen as a means of restoring ‘natural’
reproductive function. The claim of an ‘affront to womanhood’
was equally short-lived. In fact, US genders and sexualities
would have multiplied and changed through their encounters
with assisted reproductive technology, with IVF enabling
biological parenthood for single individuals, same-sex couples,
and trans individuals, thus detaching essentialist elisions
between a two-gender (male/female) system, heterosexuality
and biological reproduction.
Maverick physician Dr Landrum Shettles, who later became
known in another controversial area of assisted reproductive
technology, sex selection (Shettles and Rorvik, 1970), and who
was based at the NewYork-Presbyterian Hospital, reportedly
carried out the first known clinical IVF procedure in the USA 5
years before it eventually succeeded in the UK. Shettles
covertly arranged a course of IVF treatment for private patients
Doris and John Del-Zio in 1973. The controversial procedure
was interrupted prior to embryo transfer by Shettle’s senior
colleague Raymond VandeWiele, the Chair of the Department,
who objected to it on ethical and moral, as well as legal
and professional, grounds (Henig, 2006). Vande Wiele claimed
that the procedure violated federal regulations and thusendangered the hospital’s grants, that a resultant child might
be abnormal, which might lead to lawsuits, and that the
procedure was unsterile. In the first of many US IVF-related
lawsuits, the Del-Zios sued the hospital, and eventually won a
modest settlement. This case slowed down IVF in the USA,
especially NIH-funded research, and it took the successful birth
of Louise Brown in the UK to enable US researchers and
physicians to resume clinical IVF.
Wife-and-husband physicians Gorgeanna and Howard
Jones began to build the first US IVF clinic at the Eastern
Virginia Medical School in 1978, buoyed by the news of the
world’s first successful IVF pregnancy in the UK, and after
their official retirement, the Joneses drew on work they had
done in the summer of 1965 with Bob Edwards at Johns
Hopkins to establish proof of principle for in-vitro human
fertilization. They went on to become the doyens of US IVF.
Gorgeanna Seegar Jones (1912–2005) was a gynaecological
endocrinologist, based at Johns Hopkins School of Medicine.
Prior to her role in establishing US IVF, she was already well
known for her work on pregnancy testing using placental
human chorionic gonadotrophin (HCG), and for pioneering
progesterone treatment to prevent miscarriage. Howard W
Jones (1910–2015) was a gynaecological surgeon who also
spent most of his career at Johns Hopkins (Gosden, 2015). He
is known today not only for having established IVF in the
USA, but also for having done the biopsy from African
American cervical cancer patient, Henrietta Lacks, that led
to the immortalization of the HeLa cell line, and for his role
in the history of US sex reassignment surgery, having carried
out genital feminization surgery upon circumcision injury
victim David Reimer, who later committed suicide because of
gender dysphoria. In 2010, the year Robert Edwards received
the Nobel Prize in Medicine, Howard Jones was honoured by
the American Society for Reproductive Medicine. He turned
100 that year (Jones and Crockin, 2010).
The Joneses opened their flagship Jones Institute for
Reproductive Medicine at the Eastern Virginia Medical School
in March 1980, funded in part by a grateful, wealthy former
patient (Jones, 2014). Although the Joneses initially used the
Edwards and Steptoe natural cycle protocol that had led to the
birth of Louise Brown, they failed to establish any pregnancies
prior to the opening of the Institute. Reproductive endocrinol-
ogist Gorgeanna Jones decided to try the emerging Australian
IVF standard of hormonal stimulation to increase egg yield
and to bring the timing of IVF under greater clinical control.
Subsequently, most US clinics used hormonal stimulation
protocols as the default approach to IVF. On 28 December
1981, Elizabeth Jordan Carr, the first US IVF baby, was born. By
the time of Elizabeth Carr’s birth, five other women in the USA
were pregnant via IVF, four also through the Jones Institute and
one at the Los Angeles clinic of Dr Richard Marrs at the
University of Southern California Hospital. At least five clinics
had opened by this time: in addition to the Jones Institute and
Dr Marrs’ clinic, Dr Alan DeCherney established a programme at
the Yale University Medical School, and two clinics were
launched in Texas. US IVF had begun.
Advocacy and research on, about and with IVF accompanied
the growth of US IVF itself. For example, since the mid-1980s,
feminist scholars have expressed concern regarding the
potential exploitation of low-income women working as
surrogates, the hyper-medicalization and commodification of
reproduction, the ableism implicit in the increased prenatal
130 C Thompsonscreening linked to IVF, and inequities in access along lines of
race, class, sexual orientation and family form, disrupting from
the start the idea that IVF simply increased reproductive
liberty and choice (Asch, 1989; Allen, 1991; Arditti et al., 1984;
Corea, 1985; Rothman, 1988; Saxton, 1984). Scholars have also
documented the voices and experiences of the infertile in the
USA, and the impact of infertility on personal, gender and
family identity (Becker, 1997, 2000; Greil et al., 2011;
Sandelowski, 1993). Over time, scholars have continued to
analyse the racialized, ableist, class-based, heterosexist and
gendered organization of assisted reproductive technology as
well as its role in challenging heterosexist and nuclear family
and reproductive norms (Becker et al., 2006; Bell, 2009; Culley
et al., 2009; Mamo, 2007; Quiroga, 2007; Thompson, 2005,
2009). They have also continued to theorize the role of the law
and the highly capitalized role of biomedicine in redefining
reproduction and the family (Almeling, 2010; Kramer and
Cahn, 2013; Spar, 2006).
Similarly, natural scientists, clinicians, industry researchers
and university-based researchers in the USA have engaged in
research to improve the efficiency and success rates of assisted
reproductive technology, to understand fundamental embry-
ology, reproduction and pregnancy, and to leverage the
biological potential of the leftover products of IVF. Shortly
after the 1973 Supreme Court decision in Roe vs Wade made
abortion legal in the USA, the US Congress made it illegal to
provide federal government funding for human embryo
research. Members of Congress wanted to make sure that the
government wasn’t in the business of encouraging women to
have abortions so as to provide materials for research. It was a
rockier road setting up the interface between infertility clinics
and human embryonic stem cell research in the USA than in
some other countries, although private funding and various
state initiatives, such as California’s Proposition 71, pushed the
research ahead (Thompson, 2007, 2008, 2013). Thus, the
stipulation against federal funding for research using human
embryos has persisted since 1995 as the Dickey-Wicker
Amendment, despite numerous national commissions, exemp-
tions for foetal tissue research, the rise of clinical IVF and the
stem cell wars. (The text known as the Dickey-Wicker
Amendment is at Section 509 of Title V in the Omnibus
Appropriations Bill of 2009, signed by President Obama after
his repeal of former President Bush’s stem cell policy:
see http://www.gpo.gov/fdsys/pkg/BILLS-111hr1105ih/
pdf/BILLS-111hr1105ih.pdf).
The rise of easy-to-use, accurate CRISPR-associated protein
systems for gene editing, and the 2015 publication of a
scientific paper on human germline genome editing using
unwanted, non-viable embryos from IVF, suggest that these
complex constitutional relations between the ongoing morato-
rium on federal funding for research that destroys embryos, IVF
and cutting edge biomedical research will continue in the US
context (see http://www8.nationalacademies.org/onpinews/
newsitem.aspx?RecordID=09142015).The social, political and religious context
The abortion debate also shaped the social, political and
religious context of the emergence of US IVF. Although many
patients and practitioners are secular, it is not uncommon
for religion to be evident in US IVF clinics, not only throughits shaping of the abortion debate, but also in the values and
practices patients and physicians bring to their treatment
(Thompson, 2006). Despite restrictions on embryo research,
there is no official national position on the beginning of
life in the USA from which to regulate IVF. Catholics
and Evangelical Protestants tend to believe life begins at
conception, and this view is associated with, although by no
means confined to, members of the Republican Party. Many US
Anglicans, Muslims, Mormons and Jews, and many secular
Americans, consider the beginning of life to be a post-
conception version of personhood, based on such things as
implantation, foetal ability to suffer, or viability, which might
be marked by the development of the primitive streak,
quickening, or the ability of a foetus to live outside the
mother’s body. Scientific facts about embryonic and foetal
development, the state of medical care of premature infants,
whether or not the pregnancy in question is the result of rape
or incest, whether themother’s physical or mental health is at
risk, whether there are foetal ‘anomalies’, or whether there
are severe economic stressors, are all factors known to affect
people’s views on the acceptability of abortion in the USA.
Practitioners and intended parents in IVF clinics, regardless of
their views on abortion, treat embryos inways that foreground
the embryo’s life potential. Restrictions on federal funding of
embryo research after the passage of Roe vs Wade set the
fundamental structure of US IVF, whereby it was not federally
funded or specifically federally regulated, but was permitted
with private funding in those states with appropriate legisla-
tion. This private and devolved picture has continued to this
day, with assisted reproductive technology market pricing
quickly getting established in permissive states. The absence of
public funding has been exacerbated by, and become part of,
the unequal access to healthcare. US residents’ access to IVF
has been stratified from the start by ability to pay. Because of
correlations with socioeconomic status, a person’s chance of
accessing IVF as a form of reproductive assistance in the USA
correlates with their race, class, disability and citizenship
status, as well as withwhere they live and their age. In sum, IVF
entered the clinical field within a longstanding US history of
healthcare disparities.
Another important context was that surrounding adoption.
A perceived shortage of US children available for adoption,
critiques of the racial supremacy implicit in inter-racial
adoption, and increasing barriers to overseas adoption com-
bined with a rise in genetic ways of thinking of parenthood all
push the involuntarily childless to seek out IVF rather than
adoption. Legal adoption continued to be difficult to access in
the USA and abroad for singles and lesbian, gay, bisexual,
transgender (LGBT) singles and couples, and assisted repro-
ductive technology offered a means to parenting for different
family formations (see Goldberg and Allen, 2012; Simon and
Roorda, 2000).Public reception and debate
The birth of the first US IVF baby, Elizabeth Carr, was
announced in the New York Times in an article entitled,
‘Test-tube’ Baby Born in US, Joining Successes Around the
World (Sullivan, 1981). TV stations and newspapers around
the nation carried the story, but probably because, as the
article’s title makes all too clear, the USA was not one of the
131IVF Histories USAvery first countries to have an IVF birth, and because the
procedure was politically controversial, it did not have the
same resonance as the first births in other nations. Now
married and the mother of a ‘normally’ conceived child,
Elizabeth Carr Comeau has never had the same kind of
household name recognition as Louise Brown in the UK.
The US public reception of IVF had different phases.
James Watson predicted at the 1974 Congressional hearings
that followed on from the Roe vs Wade decision legalizing
abortion that IVF would provoke widespread moral outrage.
In the early days of clinical US IVF, the procedure was
controversial among US Catholics; for example, Bishop Edward
Head of the Roman Catholic diocese of Buffalo spoke against
the opening of what would have been one of the first clinics at
the State University of New York in Buffalo. Throughout this
early period common concerns were the depersonalization of
reproduction and the destruction of unused embryos. By the
early 1990s, some states were beginning to pass bipartisan
legislation allowing for coverage under health insurance
schemes for IVF, on the grounds that IVF promoted family
building. Later, Protestant Evangelicals and some Republican
politicians with whom they were associated would become
vocally opposed to embryo research in politically visible ways.
Accordingly, they came out in opposition to any form of
assisted reproductive technology that destroyed embryos,
arguing that each embryo was a unique and precious person
and that there are no such things as ‘leftover’ embryos from
IVF. This led, for example, to showcasing children at Congres-
sional stem cell hearings in 2005 born through the Nightlight
Christian Adoptions Snowflakes™ embryo donation and adoption
programme (https://www.nightlight.org/snowflakes-embryo-
donation-adoption/).
Over time, class-, race- and gender-drenched stories flared
up in the media, including in particular stories about
high-profile custody-related lawsuits and clinical errors, and
exposés of the exorbitant prices paid for certain kinds of egg
donors, IVF-created mega-multiple births, and social egg-
freezing ‘parties’. In Calvert vs Johnson (Cal. Sup. Ct., 5 Cal4th
84, 851 P.2d 776 [1993]), a precedent-setting landmark legal
case, the commissioning parents and providers of the egg and
sperm for IVF with surrogacy, Filipina American Crispina
Calvert and Caucasian Mark Calvert, sought a declaration
that they were the legal parents of the baby being carried by
African American Anna Johnson, their contracted gestational
surrogate. The court concurred with the plaintiff, overruling
previous California law that granted presumptive motherhood
to the woman who gave birth. This ruling played a part in
cementing the concept of ‘intentional parent’ and making the
genetic link more important than the gestational or metabolic
one in legal determinations of biological motherhood in the
USA.
Over the history of US IVF, errors have periodically made
the news. With time, it became more and more important to
account for every single human gamete and embryo and for
their chains of custody to be accurately recorded and
respected, in contrast to the days of Rock and Menkin. In
1995, Dr Ricardo Asch, then Chief of the University of
California, Irvine’s Centre for Reproductive Health, was
accused of retrieving eggs without permission from some
women and using them in the IVF procedures of other women,
leading to the birth of approximately 15 children to the
‘wrong’ (genetically unrelated) mother. Fertility drug sideeffects, such as ovarian hyperstimulation syndrome, and
pregnancy complications, have also plagued the sector. As
recently as October 2015, an American surrogate carrying
twins for a Spanish couple lost her life due to pregnancy
complications.
The advent of IVF dramatically increased multiple birth
rates in the USA, causing significant risk to mother and
babies, and requiring ongoing expense and care, but also
lighting up the news. In January 2009, Nadya Suleman, the
so-called ‘Octomom’, gave birth to IVF octuplets. At first,
the media and the public greeted it as a miracle that the
babies all survived. It soon transpired, however, that
Suleman already had six children and was unemployed; she
was excoriated in the media for having more children than
she could afford and for taking public assistance. The case
shone a spotlight on the risks of IVF without mandatory state
or federal embryo transfer rules. Suleman did not want to be
pregnant more than once again and she did not want to
destroy any of her embryos, and her physician, Dr Michael
Kamrava, was willing to transfer more embryos than
recommended in guidelines issued by the American Society
for Reproductive Medicine (ASRM). Kamrava subsequently
lost his medical licence.
Media coverage of US IVF has also played a part in new
kinds of gendered embodiment among elites related to
relentless pressures to get and stay ahead. By the late 1990s,
egg donation clinics and couples looking for egg donors
began to offer large sums for the right kinds of donors,
targeting elite college campuses. Sums upwards of $50,000
were rumoured, in exchange for donors claiming the right
ethnicity, high SAT scores and good looks, although specific
claims cannot be confirmed. In the mid-2010s, following the
declaration by the ASRM that egg freezing was no longer
experimental (ASRM, 2013), egg-freezing cocktail parties
took the nation by storm, as corporations such as Facebook
and Apple offered egg-freezing coverage, promising women
a rain check on reproduction so as to compete effectively
with men in the tech industry (Cussins, 2014).The current scope of US IVF
Growth of US IVF since Elizabeth Carr’s birth in 1981 has been
rapid. In 2013, the latest year for which there is full data, there
were 467 reporting assisted reproductive technology clinics in
the USA. Reporting to the government agency Centres for
Disease Control and Prevention (CDC) is mandatory, and the
Fertility Clinic Success Rates Report from 2013 puts the
number of assisted reproductive technology cycles performed
in the USA in that year at 190,773, approximately 50% higher
than 10 years previously. For the 2014 report, efforts were
made to make the data more accurate by accounting for egg
and embryo freezing, which can separate egg retrieval and
pregnancy by many years. Approximately 1.5% of children
born in the USA in 2013 were born via assisted reproductive
technology. This masks regional variations, with a high in
Massachusetts (4.8%), and a low in Puerto Rico (0.2%)
(Sunderam et al., 2015).
This data-rich snapshot of the contemporary scope of US
IVF is possible because of the unique history of IVF in the
USA. In the distinctive and comparative regulatory vacuum
of the USA described above, data collection emerged as a
132 C Thompsonmajor policy tool, helping the sector to make the case to and
with professionals, patients/consumers and the government
that the industry could adequately self-regulate. In 1986,
the Society for Assisted Reproductive Technology (SART), a
professional society set up for results reporting, began
collecting data from member clinics in collaboration with
the CDC. In response to concerns about false advertising,
and in conjunction with patient activism and the Federal
Trade Commission, The Clinic Success Rate and Certification
Act of 1992 [Section 2(a) of P.L. 102–493 (42 USC. 263a-1(a))]
was passed, mandating that the CDC collect data on clinic
success rates. Since 1997, SART and the CDC have collected
yearly data on assisted reproductive technology treatment
types and outcomes per cycle, by clinic, state and nationwide,
covering over 95% of US clinics. In 2001, the CDC established
the States Monitoring ART (SMART) Collaborative, which links
state surveillance data on pregnancy outcomes to assisted
reproductive technology success rates. In 2002, the CDC
published the first assisted reproductive technology surveil-
lance summary, and in 2006, the National ART Surveillance
System (NASS) was formed in conjunction with patient
advocacy (RESOLVE, Path2Parenthood and Livestrong Fertility)
and professional partners (the American Society for Reproduc-
tive Medicine and SART).
IVF-related data collection became an area of constant
innovation that provided reliable comparative data on
clinics to consumers. As the data collection efforts became
more sophisticated, they began to make it possible to pose
and answer questions that would forge links with public
health that in other countries were built in from the start. As
well as data on diagnosis, clinic procedure and outcome, the
2006 NASS included data on patient demographics and on
multiple births, prematurity and low birthweight. These
additional factors provided data for the first time to address
social and public health problems of the risks of assisted
reproductive technology and unequal access, and to help
policymakers effect change, for example through recom-
mendations to reduce the number of embryos transferred
and so reduce multiple and low birthweight births. At the
time of writing, the SART clinic outcome reporting system
database (SART CORS) has been linked in a collaboration
with the Massachusetts Pregnancy to Early Life Longitudinal
(PELL) data system to make the MOSART database, which will
eventually provide access to long-term epidemiological data
for women undergoing assisted reproductive technology
procedures and the children born through the procedures.
Data may not seem like a conventional form of governance,
but it has emerged as such in the US context, to an impressive
degree.Paying for IVF
assisted reproductive technology is expensive in the USA for
most people, although the cost varies dramatically accord-
ing to the region and the procedure required. IVF has thus
been disproportionately used for wealthier people in the
USA, and this manifests in every aspect of the history and
current landscape of clinics and debate. In the light of the
foregoing discussion of national data collection as a proxy for
federal regulation, it is interesting to note that rigorous per
cycle and per clinic data is recorded only for the outcome ofprocedures and not on cost. Clinic-specific costs and
strategies for paying can be found on clinic and patient–
consumer websites but they are not part of the national
reporting structure.
Per cycle costs of IVF are difficult to estimate but the
figure most often cited as typical for a ‘fresh’ cycle (no
freezing required) using a couple’s own gametes is around
$8000–15,000, including the fertility drugs and monitoring.
Intracytoplasmic sperm insertion (ICSI) adds another
$1000–1500. Third-party involvement usually increases IVF
costs considerably. For example, egg donation adds around
$20,000, including agency and legal fees, but can be much
higher for desirable egg donor traits. Surrogacy can easily
cost more than $100,000 if legal and medical fees are included,
although some US intended parents travel overseas to contract
the services of a surrogate to reduce costs. Pre-implantation
genetic diagnosis for unexplained infertility and for known
carriers of certain diseases adds $4000-7500 extra per cycle. Egg
freezing, although not a treatment per se, costs approximately
$15,000 initially, to stimulate the production of eggs and then
freeze them, and then up to about $1000 a year in storage costs
to which must then be added the cost of subsequent thawing
and IVF. Embryo donation is sometimes marketed as a cheaper
option than regular IVF because intended parents do not have to
pay for the embryo creation part of the IVF cycle, but given that
embryo donation is usually offered after unsuccessful IVF, it also
tends to add to total treatment costs.
The insurance picture in the USA is a patchwork. In 15
states some fertility procedures are covered if you have the
right health insurance and have opted into the right benefits
(Arkansas, California, Connecticut, Hawaii, Illinois, Louisiana,
Maryland, Massachusetts, Montana, New Jersey, New York,
Ohio, Rhode Island, Texas and West Virginia). Of these 15
states, 8 have IVF mandates. These, listed in the temporal
order in which coverage was enacted, are Arkansas (1987),
Massachusetts (1987/2010), Hawaii (1989/2003), Rhode Island
(1989), Illinois (1991/97), Maryland (2000), New Jersey (2001)
and Connecticut (2005).
This patchwork leaves those living in states without
insurance coverage and those without the right insurance in
covered states, with no coverage for IVF. Even within states
with IVF insurancemandates, there are exceptions to mandates
to offer or cover fertility treatments, such as for small
businesses, religious organizations and for the self-employed,
and many employers do not offer health insurance at all. In
general, the more precarious your socioeconomic situation, the
less likely you are to have insurance coverage for IVF (King and
Harrington-Meyer, 1997). As ethnographers of US assisted
reproductive technology have documented, people have found
informal ways of rendering treatment more affordable from its
earliest days, by, for example, buying fertility drugs inMexico or
Canada, or by having parts of the treatment and care classified
by practitioners under billable codes such as ‘pelvic pain’
(Thompson, 2005).
Caught up with advertising and markets, assisted repro-
ductive technology clinics in the USA have developed a
three-pronged approach to paying privately for assisted
reproductive technology for those unable to afford up-front
out of pocket costs: refunds, financing and low-cost IVF.
Refund programmes usually involve buying a package of IVF
treatments at a reasonable cost, and if you don’t get
pregnant after a set number of cycles, you get your money
133IVF Histories USAback. This financial model is premised on many people
getting pregnant in fewer than the paid-for number of
cycles. Certain clinics offer low-cost financing specifically
for treatment. For example, WINFertilityRx works with
clinics nationwide to offer loans for fertility drugs and/or
treatments, and is touted for its simple application proce-
dure and the firewall protecting patient credit scores.
Low-cost IVF takes two forms. Some clinics offer discounts
to members of certain groups of people such as teachers,
military, first responders and low-income couples. For exam-
ple, Sher Institutes for Reproductive Medicine, which has
nationwide clinics, offers free or discounted treatments
through its ‘Giving Back’ programme, and discounted packages
for community service providers and those making under
$55,000 a year. The International Council on Infertility
Information Dissemination, Inc. (INCIID) runs a limited scholar-
ship fund, with practitioners at given clinics donating treat-
ment to successful applicants; the latter have to apply and
have to be deemed worthy and needy (http://inciid.org/
scholarship-faq). The other kind of low-cost programme
involves providing a less medically intensive treatment
protocol. Several clinics around the nation offer micro-IVF, or
mini-IVF, which includes lower doses of fertility drugs and less
monitoring and lab manipulation, but is usually only available
to younger patients with no male factor contributing to the
infertility.
In general, public funding is meagre. Public programmes
such as the federal health insurance system, Medicare,
which provides basic healthcare to those living with
disabilities (and those over 65, who are not at issue here),
covers childbirth and pregnancy but not IVF. State-specific
health insurance systems offer emergency and other basic
care to low-income individuals, and typically cover some
fertility services, especially if medical necessity can be
shown, but do not cover IVF. The Affordable Care Act (ACA,
the so-called ‘Obamacare’) does not have to offer IVF except
in states where there was an IVF mandate in place before
2012, and where the state benchmark for determining
Essential Health Benefits (EHB), such as a Health Mainte-
nance Organization (HMO) plan, includes that mandate. The
ACA covers IVF in six states: Connecticut, Hawaii, Illinois,
Massachusetts, New Jersey and Rhode Island.
In states with insurance coverage for IVF, age limits vary
from state to state. Insurance typically only covers IVF with
couples’ own gametes, often specifies heterosexual mar-
riage or coupledom, and requires the woman to be under 40
to 45 years of age, depending on the state. While a male
intended parent’s age is not specified, sperm and egg donors
and surrogates all also have to fall within strictly specified
age limits, and must be free of certain diseases, tall (for
sperm donors), thin (for egg donors) and appropriately
motivated and compliant (for surrogates and donors). The
proportion of public IVF among the whole is thus tiny; if
state-mandated insurance is taken into account, it rises
significantly, but still only covers a small proportion of total
numbers of assisted reproductive technology cycles.
In summary, the history of US IVF would be incomplete
without emphasizing the role that having to pay for IVF has
played both in selecting for some kinds of patients over
others and in shaping IVF as a medical market. As noted in
the section above on the origins of US IVF, IVF in the USA
took off using fertility drugs rather than natural cycles, andhas never been an obvious fit for low-stimulation micro-IVF.
Nonetheless, in a nation without universal healthcare, and in
which medical approaches to involuntary childlessness are
not widely covered by health insurance, there is a large
unmet need for IVF among those who do not have the ability
to pay. It is customary to think of micro-IVF as most
appropriate for low-resource countries, and yet its expan-
sion would be invaluable in the USA in improving access and
inclusion and reducing eugenic market trends.Regulation
There are three main kinds of federal regulation of the practice
of IVF. First, laboratories are regulated under the Clinical
Laboratory Improvement Act (CLIA) of 1988; second, the drugs
and devices used in IVF are regulated by the Federal Food and
Drug Administration (FDA), and finally, the Fertility Clinic
Success Rate and Certification Act discussed above is imple-
mented by the CDC in conjunction with its partners. In addition,
when patients are part of research protocols for drugs or
devices, they are covered by federal human subjects’ protec-
tion. In addition to the Dickey-Wicker Amendment appropria-
tions bill rider that prohibits the Department of Health and
Human Services from using federal funds to create or destroy
embryos purely for research purposes, many individual states
also prohibit embryo destruction and research and set restric-
tions on IVF.
As mentioned in the section on data collection above, IVF
and assisted reproductive technology are also self-regulated
through continuous action by and on behalf of patient
advocacy organizations such as RESOLVE and professional
organizations led by the ASRM. Scholars have explored the
consumer subjectivity, self-regulatory rational and market
dynamics of the self-regulation of US IVF (Becker, 2000;
Spar, 2006; Thompson, 2005). Often working together,
patient and professional organizations address ethical,
technical and regulatory issues by committee, at annual
meetings, in informational booklets and guidelines, in data
reporting standards and through the media. This kind of
voluntary self-regulation produced by interested parties
cannot directly represent the needs and rights of the general
public, but perhaps because prospective patients rely on
success rates when choosing clinics, compliance with
proactive reporting is the overwhelming norm.
Because of the low levels of public funding for assisted
reproductive technology and healthcare in general, low
levels of federal oversight, regulatory and insurance differ-
ences among the states, and abortion and embryo politics in
the USA, assisted reproductive technology is widely seen as
under-regulated in the USA. This stands in contrast to some
European countries, such as the UK, where IVF is sometimes
portrayed as over-regulated. The absence of comprehensive
federal regulation has had the effect of keeping assisted
reproductive technology more accessible to non-low income
LGBT and single individuals than is the case in many nations
that regulate assisted reproductive technology more system-
atically. It has also kept many assisted reproductive technol-
ogy procedures legal in the USA that have been banned
elsewhere, such as commercial surrogacy and compensated
egg donation. This inclusivity of different family forms and
permissiveness of reproductive markets attracts not only US
134 C Thompsonusers but also reproductive tourists from abroad. In general,
the USA sends its own reproductive travellers abroad to seek
advantageous pricing, and receives reproductive travellers
seeking procedures that are illegal or otherwise unavailable in
their own countries. The rise of reproductive travel both in
and out of the USA speaks of the need for supra-national,
cross-border oversight that is sensitive enough to harmonize
with very different national settings and IVF regulatory
regimes.What is considered incest?
US views on incest in the context of IVF can be seen in the
ASRM Ethics Committee 2012 paper on the subject, Using
Family Members as Gamete Donors or Surrogates (ASRM,
2012). In this document, no national, community,
ethno-racial, sexual orientation-based or third/fourth/
fifth-party restrictions in relation to the marital bond are
raised. The only kinship relationships considered are moth-
er/father/child/sister/brother/uncle and aunt. The authors
separate out genetic and social relationships, and don’t
consider pregnancy without genetic relationship to be
relevant to true incest. They summarize what they consider
to be incest in a table, under the headings sperm donation,
ovum donation, traditional surrogacy and gestational surro-
gacy (p. 798–799).
The Committee notes many concerns with intra-familial
third-party assisted reproductive technology procedures
that they do not define as incest. Thus, they point to the
potential for coercion, especially in daughter-to-mother egg
donation or surrogacy, and son-to-father sperm donation;
age-related risk of increased mutation rates in gametes in
father-to-son or mother-to-daughter donation; the risk of
undue obligation resulting from mother-for-daughter surro-
gacy, and the wider effects on familial relationships, such as
a sister-to-sister donation meaning that the social aunt is the
genetic mother. Incest per se is discussed in two kinds of
cases. The first are those cases where there is actual
‘consanguineous relationship’, which they define by the
combination of a father’s or brother’s or son’s sperm with his
daughter’s or sister’s or mother’s egg, respectively (whether
or not the offspring is gestated in the sister’s or daughter’s
or mother’s womb). The Committee advises that this kind of
incest ‘should be prohibited’. Second are the cases where the
procedure ‘may create the impression of incest’, such as when
a woman uses donor eggs from a non-relative and donor sperm
from her brother to initiate her pregnancy; in this case, that
she is carrying her brother’s genetic child can give the
impression of incest, even though her own eggs were not
used. The authors do not conclude that these second kind of
cases should necessarily be prohibited, because they consider
them to be based on the impression rather than reality of what
they consider a consanguineous relationship.
The definition of incest that emerges is thus a genetic one
involving a child conceived with the gametes of a sibling–
sibling or parent–child pair. From this, it can be inferred
that in mainstream US biomedical society, incest is defined
narrowly compared with other parts of the world, and is
restricted to one or two generations, requires direct or
shared biological descent, and is indifferent to the marital
status and collective identities of parties to the procedure.Furthermore, US IVF spokespeople believe actual incest, as
opposed to the impression thereof, occurs only when
genetic, rather than gestational, ties are too close. This is
a national biology that IVF itself has had a hand in creating,
through making it possible to separate gestation and gamete
provision.Conclusion
IVF emerged in the USA in a political context marked by
three major factors: low levels of federal regulation and a
patchwork of regulations for reproductive technologies state
by state; the absence of a universal healthcare system; and a
politically partisan abortion debate that restricted federal
funding for research. These factors together pushed most
IVF into the fee-for-service healthcare sector. As a result,
market dynamics took hold in US IVF, increasing the products
on offer in a manner freer of common restrictions on price,
family form or treatable diagnoses than in many other
countries. Commercial surrogacy, gamete donation and
genetic screening all flourished in the more permissive
states, in a modified market form. Over time, new kinds of
patient-purchasers such as single and asexual men and
women, LGBT men and women, and overseas reproductive
tourists joined the original US-based heterosexual infertile
treatment population. The sector also became populated
with new service providers such as career surrogates and
donors, psychologists and IVF finance specialists.
The market growth of IVF in the USA was marked as much
by exclusion as by its inclusivity. The market proliferation of
IVF led to the circulation and monetization of eggs and
embryos in ways that quickly developed price stratification
according to hierarchies based on highly desirable traits in
contemporary US culture, such as academic and artistic
achievement, height in men, and thinness and attractiveness
in women. Consumers expected to be able to shop for the
procedures and donor traits they desired, and did so in ways
consistent with ableist, classist, sexist and racially suprema-
cist ideas of what kinds of children would be most desirable.
US IVF, then, has a history marked by this particular mix of
inclusiveness and exclusiveness stemming from the factors
that contributed to its low levels of federal regulation. Its
increasingly strong data collection efforts, and the salience of
professional organization and patient–consumer advocacy
collaborations with government agencies, have begun to
bridge the gap between consumer markets and public health
concerns. It remains to be seen whether US IVF can keep some
of the progressive aspects of its history alive, such as its
openness to changing family norms, while improving access,
minimizing health disparities, monitoring public health
effects, and acting where exploitation of third parties or
excessive selection of gametes and embryos is evident.References
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